Wakamoto Pharmaceutical
4512.TPharmaceutical
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥9.9bn | ¥7.8bn | ¥7.7bn | ¥8.7bn | ¥8.4bn | ¥8.9bn |
| Operating income | ¥256m | −¥458m | −¥196m | ¥141m | −¥13m | −¥755m |
| Ordinary income | ¥256m | −¥409m | −¥162m | ¥243m | ¥72m | −¥605m |
| Total assets | ¥16.5bn | ¥15.0bn | ¥15.4bn | ¥15.7bn | ¥15.0bn | ¥14.6bn |
| Net assets / equity | ¥12.0bn | ¥11.6bn | ¥12.0bn | ¥11.9bn | ¥11.5bn | ¥11.4bn |
| Operating cash flow | −¥487m | −¥592m | −¥107m | ¥632m | ¥339m | ¥163m |
| EPS (basic) | ¥6.54 | ¥1.85 | ¥3.13 | ¥3.98 | ¥6.87 | ¥-17.34 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 124 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 71 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 124 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 71 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 124 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 49 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 73 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 47 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 124 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 48 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 72 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 46 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 124 figures · EDINET |
21 more reports are still being processed.